QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=4F0406F7F57D8ABA26520ED8C959BDF2;jsessionid=1E4F977EB3F1C3E4C356E3E8D43C86E2;jsessionid=341F35ABB4332B3103C2E005326A78E8;jsessionid=7AF29192561D91B72D90126539A48D89;jsessionid=12886741E2F9B1BB790CAAA1F76C5644;jsessionid=90050983C7D3AF9AB1CE2103DA2C5622 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=4F0406F7F57D8ABA26520ED8C959BDF2;jsessionid=1E4F977EB3F1C3E4C356E3E8D43C86E2;jsessionid=341F35ABB4332B3103C2E005326A78E8;jsessionid=7AF29192561D91B72D90126539A48D89;jsessionid=12886741E2F9B1BB790CAAA1F76C5644;jsessionid=90050983C7D3AF9AB1CE2103DA2C5622